CeGaT’s business unit, Research and Pharma Solutions, is expanding its tumor profiling portfolio to support oncology research across a broad range of scientific questions. The established Comprehensive Tumor Profiling (CTP) product category has been restructured and expanded into three product portfolios. Additionally, a new product category, Focused Tumor Profiling (FTP), has been introduced to facilitate efficient and targeted analysis of tumor-relevant genes.
Comprehensive Tumor Profiling – broad insights for precision medicine
With the shift toward precision oncology, the importance of comprehensive genomic tumor profiling is growing. CeGaT‘s Comprehensive Tumor Profiling (CTP) enables the simultaneous evaluation of multiple biomarkers and the detection of somatic mutations in a single analysis. This approach supports the identification of predictive markers for targeted therapies and key immuno-oncology biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI). CTP helps guide treatment decisions, identify patients for clinical trials, and support clinical research in areas such as immunotherapy.
CeGaT‘s updated CTP category comprises three distinct product portfolios:
- Whole Genome Sequencing CTP portfolio: enabling the broadest insight into the tumor genome
- ExomeXtra® Sequencing CTP portfolio: leveraging the advantages of CeGaT’s proprietary ExomeXtra® approach for tumor analysis
- Whole Exome Sequencing CTP portfolio: applying Twist Bioscience enrichment to focus on the known coding exons of the human genome
All three CTP portfolios offer tumor-normal (TN) and tumor-only (T) products. This flexibility allows researchers to select the most appropriate setup for their specific research objectives and available sample material.
Focused Tumor Profiling – targeted, efficient, impactful
While Comprehensive Tumor Profiling provides broad insights, targeted approaches are essential for identifying mutations that drive tumor progression or confer resistance to therapy. CeGaT’s Focused Tumor Profiling (FTP) product category addresses this need with a set of focused sequencing products tailored to specific research needs. FTP products offer an efficient method to identify the best treatment option, select patients for clinical trials, and monitor a patient’s mutation status during the course of therapy.
The FTP product category includes:
- FTP TUM: Available as a tumor-normal comparison (FTP TUM TN) or as a tumor-only product (FTP TUM T). This broad panel covers over 780 tumor-relevant genes, 39 clinically relevant fusions, and selected tumor-associated pathogens.
- FTP PAT T: a focused panel of 55 genes frequently altered in tumor diseases, available as a tumor-only product.
- FTP FUS T: an RNA-based panel designed to detect tumor-relevant gene fusions, also available as a tumor-only product.
Research and Pharma Solutions support
Our team is happy to advise you on the most suitable product for your research question. For detailed information, please visit our website or contact our Research and Pharma Solutions team at rps@cegat.com.